Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5943
Title: Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions?
Authors: Demirci, Senem
Kamer, S.
Kara, G.
Yıldırım, Özgür
Esassolak, M.
Keywords: Chemoradiotherapy
Radiotherapy
Treatment outcome
amifostine
bleomycin
cisplatin
cortisone
docetaxel
epirubicin
hydroxyurea
UFT
adolescent
adult
aged
article
brain necrosis
cancer chemotherapy
cancer classification
cancer radiotherapy
cancer recurrence
clinical feature
controlled study
cranial nerve
cranial nerve paralysis
disease free survival
distant metastasis
eye disease
female
follow up
headache
human
inner ear disease
lethargy
major clinical study
male
medical literature
medical record review
multiple cycle treatment
multivariate analysis
nasopharynx cancer
overall survival
paralysis
priority journal
prognosis
retrospective study
salivary gland disease
seizure
skin toxicity
spinal cord disease
survival rate
temporal lobe necrosis
treatment outcome
treatment response
trismus
xerostomia
Adolescent
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Disease-Free Survival
Endemic Diseases
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
Nasopharyngeal Neoplasms
Neoplasm Recurrence, Local
Prognosis
Retrospective Studies
Survival Rate
Turkey
Young Adult
Abstract: Conclusion: The survival rates and prognostic factors for nasopharyngeal cancer (NPC) were found to be similar to the published series from endemic regions. Objectives: The purpose of this retrospective study was to evaluate treatment outcome and prognostic factors of NPC patients treated with radiotherapy or chemoradiotherapy in a non-endemic region. Methods: We analyzed clinical characteristics, treatment outcome, and prognostic factors of NPC patients in a non-endemic region, and compared our institution's results with the published literature including a similar patient population from endemic and non-endemic regions. Among 248 NPC patients, 71 (28.6%) were female and 177 (71.4%) were male with a median age of 48 years. Results: Within a median 59 months (range 22178) of follow-up, local recurrence developed in 22 (8.9%), regional recurrence in 2 (0.8%), locoregional recurrence in 5 (2%), distant metastases in 21 (8.5%), and both locoregional recurrence and distant metastases in 8 (3.2%) patients. Five-year locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS) rates were 83.7%, 73%, 78.5%, and 71.1%, respectively. In multivariate analysis for LRC, cranial nerve involvement (CNI) (p = 0.009) and tumor response (p = 0.004); for DFS, age (p = 0.003), CNI (p = 0.02), AJCC T classification (p = 0.05), and tumor response (p = 0.01); for DSS, age (p = 0.003), CNI (p = 0.04), AJCC T classification (p = 0.04), and tumor response (p = 0.01); for OS, age (p < 0.001), AJCC T classification (p = 0.005), and tumor response (p < 0.001) were significant prognostic factors. © 2011 Informa Healthcare.
URI: https://hdl.handle.net/11499/5943
https://doi.org/10.3109/00016489.2011.560188
ISSN: 0001-6489
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

6
checked on May 11, 2025

WEB OF SCIENCETM
Citations

3
checked on May 13, 2025

Page view(s)

96
checked on May 11, 2025

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.